Literature DB >> 3119516

High-dose intravenous gammaglobulin for chronic inflammatory demyelinating polyneuropathy.

B Currò Dossi1, F Tezzon.   

Abstract

We report our preliminary experience of high-dose intravenous gammaglobulin in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) selected for inefficacy or severe side effects of steroid and immunosuppressive treatment. Our treatment proved safe and effective, reversing the disability of CIDP, the improvement being temporally related to the commencement of intravenous high-dose gammaglobulin. The possible mechanisms of action are discussed.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3119516     DOI： 10.1007/bf02335733

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN： 0392-0461


  4 in total

1.  New therapeutic perspectives for demyelinating retrobulbar optic neuritis.

Authors:  B Currò Dossi; A Amadori; C Cirafisi; S Lorusso; M Pasquinelli; M G Piscaglia; A Ravasio
Journal:  Ital J Neurol Sci       Date:  1998-02

2.  Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating neuropathy not responsive to other treatments.

Authors:  R Nemni; S Amadio; R Fazio; G Galardi; S Previtali; G Comi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

Review 3.  Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy.

Authors:  P A van Doorn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

4.  Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study.

Authors:  M Vermeulen; P A van Doorn; A Brand; P F Strengers; F G Jennekens; H F Busch
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-01       Impact factor: 10.154
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.